Talecris Biotherapeutics (TLCR) is one of the more recent successful IPO stories as the company raised capital and began trading on October 1. The IPO was priced at $19.00 per share and underwritten by an all-star cast of investment bankers including Morgan Stanley (MS), Goldman Sachs (GS), Citigroup (C) and JPMorgan Chase (JPM). On the first day of trading, investors were rewarded with an 11% return as the stock bolted out of the gate. 
Over the next month, the stock began to cool off as is often the case with new issues. In early December, TLCR breached the all important IPO price of $19, but within two weeks the stock began to mount a recovery. This is a perfect example of how underwriters and IPO investors can often be counted on to support a new issue very close to the IPO price. It’s important for the underwriters to have the issues trade above the offering price, because it makes their job easier when peddling the next IPO to investors. So often for quality IPOs, it is a good strategy to buy additional shares when the stock tests the initial price point.
The business model for Talecris appears to be very sound, as the company is experiencing strong revenue growth and generating impressive strength in earnings. The company is a world leader in plasma based therapies and has strong command over its niche of the medical business. One concern could be that the company receives 70% of its revenue from its two main products (Gamunex IVIG and Prolastin A1PI). I’m not extremely experienced when it comes to the medical industry, but it appears based on market share and revenue trends that the company is very successful in its product lines. The third quarter was a strong period for TLCR with revenue growth of 12.9% and EPS of $0.38 which represents an increase of 72.7% over last year. It appears that the company has been able to reduce expenses through vertically integrating its supply chain which has led to stronger gross margins. The IPO transaction allowed the company to pay down a portion of its debt leading to lower interest expense which further helps to bolster earnings.
Our third quarter results reflect the continued demand for Gamunex, our brand of IGIV, as well our success in building a vertically integrated plasma supply chain to ensure a continual supply of Gamunex. ~Lawrence D. Stern, CEO
As far as debt is concerned, the company still has long-term liabilities north of $1 billion. The liabilities are offset by $630 million in inventory and a healthy balance of accounts receivables, but the high level of debt could still become a concern should there be any unexpected changes in the revenue stream. While it is still too soon after the IPO, I would not be surprised if the company issued additional equity in the first few quarters of 2010 in order to pay down debt. This would dilute current shareholders, but would also lead to a more stable capital structure.
Analysts are expecting the company to earn $1.52 per share in 2010 which is probably reasonable given the strong management team, growing revenue base, and cost cutting initiatives. At the current price near $21, the stock is trading at a multiple of 14 which seems a bit conservative considering the earnings growth. Some caution is in order due to the debt level, but a multiple of 20 would not be unreasonable. If we see medical stocks rebound in the aftermath of health care reform (as I expect we will), TLCR could ride the trend and see a much higher multiple.
So at this point it looks like the risk/reward ratio is very good. $19.00 remains an important level to watch as a breach of this level would cause me to stop out my position. On the other hand, the stock has the potential to trade through $30 and yield a 40% plus return. The next six months should be a positive period for TLCR and its investors and I look forward to seeing what kind of growth management can generate.
FD: Author does not have a position in TLCR
Enjoy this article? Sign up for the ZachStocks Newsletter,
Your source for Sound Market Commentary, Growth Stock Analysis and Successful Investment Strategies
